BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Biotech Bay

  ReCor Medical Announces Results from Landmark RADIANCE-HTN TRIO Study, Showing Clinically Significant Blood Pressure Reduction with the Paradise Ultrasound RDN System in Patients with Resistant Hypertension

  ReCor Medical, Inc., a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd., presented the primary endpoint data from the randomized sham-controlled RADIANCE-HTN TRIO study.

  May 16, 2021

   · 

  4 min read
• Biotech Bay

  Applied BioMath, LLC Provides Systems Pharmacology Modeling in Oncology for Antengene

  Applied BioMath, the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, was selected by Antengene Corporation to provide systems pharmacology modeling in immuno-oncology.

  May 16, 2021

   · 

  2 min read
• Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial

  Antengene Corporation Limited announced ATG-101, a novel PD-L1/4-1BB bispecific antibody being developed by the company, has completed its quantitative and systems pharmacology modeling that will provide data guiding the first-in-human study of ATG-101.

  May 16, 2021

   · 

  6 min read